Abera Bioscience AB

Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience. Our founder and CTO, Prof. Joen Luirink is a world-leading expert on bacterial protein trafficking and membrane transport systems and his vast knowledge in the area provided the basis for Abera’s innovative vaccine delivery platform. Abera’s novel vaccine delivery platform was first developed for the production of difficult-to-express proteins by bacteria. But when we developed the possibility to display antigenic proteins on bacterial surfaces, the idea of exploiting it for vaccine delivery was born. Abera is dedicated to the development of novel vaccines to save lives and increase health globally.